surmount-1 tirzepatide non-diabetic obesity trial for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program - Roux - 2023 - Gastrointestinal tolerability and weight reduction

The dream: a once-a-year obesity shot When Jonsson goes into full crystal ball-gazing mode, he imagines a future where these drugs could become as convenient as flu vaccines though affordable weight-loss medications may remain a pipe dream

Combining cardiovascular exercise with strength training produces superior outcomes compared to either modality alone

The combined modulation of gut bacteria toward a more metabolically favorable profile may support better gut barrier function, reduced systemic inflammation, and improved metabolic responses over time

Plain water is not enough if you are eating significantly less food

Mounjaro (tripeptide) is a newer medication that offers more significant weight loss results with the convenience of once-weekly injections

However, the slower tirzepatide titration may improve tolerability by allowing more gradual adaptation